Biogen Inc BIIB

$247.13 -4.28 (-1.70%)

Valuation

Market cap
37,163,428,000
Revenue TTM
$9,890,600,000
Net income TTM
$1,292,900,000
P/E (trailing)
21.29
P/E (forward)
20.12
Profit margin
13.07%
Debt to equity
0.39

Trading

Volume
1,269,400
Avg volume
1,207,038
Day's range
$243.58 – $252.09
Shares out
147,820,000
Stochastic %K
20%
Beta
0.10
Analysts
Moderate Buy
Price target
$269.56

Price

Company profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etan...

Show more

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
617 679 2000
Website
https://www.biogen.com
Address
225 Binney Street, Cambridge, United States

Latest news

Stocktwits

BiotechSwings Nov 19, 8:26 PM
Two Phase 3 readouts in the same window and $BIIB is acting like December is just another month imo litifilimab in systemic lupus, TOPAZ 1 and TOPAZ 2, topline lands in the first half of December trading near 247 today, down 1.7% off a 251.41 close and still close to the 261 high from Nov 9. two shots on goal, one real clock
0 replies
LibertarianTreehugger Nov 18, 11:47 PM
Biogen Reports Encouraging Two-Year Results for Alzheimer's Drug: https://jlsfund.substack.com/p/biogen-reports-encouraging-two-year $BIIB
0 replies
SparkyReturns Nov 18, 5:37 PM
$ICU What SeaStar is doing will affect many other companies since the SCD can help calm the cytokine storm caused by so many indications. $MRNA $PFE $BIIB $RHHBY
2 replies
Rayvio_News_Filter Nov 18, 4:38 PM
$BIIB 🏥 Biogen presented new two-year Phase 2 CELIA data suggesting its investigational tau-reducing Alzheimer's therapy diranersen (BIIB080) may have growing clinical benefit with longer treatment. Timely market event
0 replies
teddymoney Nov 18, 4:04 PM
$UNH $GDRX $LLY $BIIB $WBA https://drugalt.com will change healthcare by giving people information and drug price transparency, can’t wait till it goes otc
0 replies
Rayvio_News_Filter Nov 18, 4:01 PM
$ESALF · $BIIB 🏥 Eisai and Biogen present new three-year real-world LEADER data from 560 patients showing LEQEMBI was associated with a 76% lower rate of progression to moderate or severe Alzheimer's disease dementia versus a matched natural history cohort.
0 replies
AdamBrennan2 Nov 18, 11:04 AM
$BIIB makes drugs for brain and nerve diseases like ms and alzheimers, but it doesnt build the pipeline alone roche's genentech is behind the anti-cd20 drugs and eisai shares leqembi, where biogen gets 50% of net product revenue to me this looks less like one drug company and more like a hub that keeps plugging in partners the catch is that tysabri and spinraza are each over 10% of total revenue. are the partners enough to carry the next chapter? $INSM $INCY $BNTX $UTHR
0 replies
AdamBrennan2 Nov 18, 6:42 AM
$AMGN evenity is growing 38.8 percent year over year but product sales volume growth fell to just 9 percent look at the key kpis below the big growth numbers are coming from price increases and new drugs, not from volume $ALNY $MRNA $BIIB $ROIV
0 replies